Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Nov 14, 2019

SELL
$217.44 - $243.88 $287,673 - $322,653
-1,323 Closed
0 $0
Q2 2019

Aug 12, 2019

SELL
$219.29 - $241.72 $5,262 - $5,801
-24 Reduced 1.78%
1,323 $309,000
Q1 2019

May 08, 2019

BUY
$216.71 - $338.96 $5,851 - $9,151
27 Added 2.05%
1,347 $318,000
Q4 2018

Feb 14, 2019

SELL
$278.5 - $352.75 $11,975 - $15,168
-43 Reduced 3.15%
1,320 $397,000
Q3 2018

Nov 13, 2018

BUY
$293.51 - $383.83 $324,035 - $423,748
1,104 Added 426.25%
1,363 $482,000
Q2 2018

Aug 10, 2018

SELL
$257.52 - $306.91 $3,605 - $4,296
-14 Reduced 5.13%
259 $75,000
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $48,904 - $69,167
188 Added 221.18%
273 $75,000
Q4 2017

Feb 13, 2018

BUY
$307.64 - $344.58 $26,149 - $29,289
85
85 $27,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $22.7B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Midwest Professional Planners, Ltd. Portfolio

Follow Midwest Professional Planners, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Midwest Professional Planners, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Midwest Professional Planners, Ltd. with notifications on news.